M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation


*Centre for Translational and Chemical Biology and †Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH9 3JR, United Kingdom

Edited by John Kuriyan, University of California, Berkeley, CA, and approved February 22, 2013 (received for review October 3, 2012)

We show that the M2 isoform of pyruvate kinase (M2PK) exists in equilibrium between monomers and tetramers regulated by allosteric binding of naturally occurring small-molecule metabolites. Phenylnalanine stabilizes an inactive T-state tetrameric conformer and inhibits M2PK with an IC₅₀ value of 0.24 mM, whereas thyroid hormone (triiodo-L-thyronine, T₃) stabilizes an inactive monomeric form of M2PK with an IC₅₀ of 78 nM. The allosteric activator fructose-1,6-bisphosphate [F₁₆BP, AC₅₀ (concentration that gives 50% activation)] of 7 μM shifts the equilibrium to the tetrameric active R-state, which has a similar activity to that of the constitutively fully active isoform M₁PK. Proliferation assays using HCT-116 cells showed that addition of inhibitors phenylalanine and T₃ both increased cell proliferation, whereas addition of the activator F₁₆BP reduced proliferation. F₁₆BP abrogates the inhibitory effect of both phenylalanine and T₃, highlighting a dominant role of M₂PK allosteric regulation in tumor proliferation. X-ray structures show constitutively fully active M₁PK and F₁₆BP-bound M₂PK in an R-state conformation with a lysine at the dimer-interface acting as a peg in a hole, locking the active tetramer conformation. Binding of phenylalanine in an allostatic pocket induces a 13° rotation of the protomers, destroying the peg-in-hole R-state interface. This distinct T-state tetramer is stabilized by flipped out Trp/Arg side chains that stack across the dimer interface. X-ray structures and biophysical binding data of M₂PK complexes explain how, at a molecular level, fluctuations in concentrations of amino acids, thyroid hormone, and glucose metabolites switch M₂PK on and off to provide the cell with a nutrient sensing and growth signaling mechanism.

allosteric regulation | nutrient sensor | thyroid hormone T₃ | Warburg effect

The last of 10 enzymatic steps used to convert glucose to pyruvate is carried out by pyruvate kinase (PYK), which transfers a phosphate from phosphoenolpyruvate to ADP to generate ATP. There are four human PYK isoforms (1); RPYK is restricted to erythrocytes, LPYK is found predominantly in liver and kidney, M₁PK is in muscle and brain, and M₂PK is found in fetal tissues and in proliferating cells. All four isoforms are active as tetramers; M₁PK is constitutively fully active, whereas R-, L-, and M₂PKs are activated by the effector molecule fructose-1,6-bisphosphate (F₁₆BP) (2). M₂PK is a splice variant of the nonallosteric M₁PK isoform and differs by 22 amino acid residues (3). Recent quantification of the concentrations of constitutively fully active M₁PK and allosterically regulated M₂PK isoforms in both cancerous and control tissue samples has revealed that M₂PK is almost always the most abundant isoform in cancer cells, although it can also be predominant in matched control tissues (4). The up-regulation of the M₂PK isoform plays a key role in cancer metabolism (3) and explains the Warburg effect, in which proliferating cancer cells metabolize increased amounts of glucose but with no increase in mitochondrial oxidative phosphorylation (5). Regulation of M₂PK activity by the allosteric effector F₁₆BP provides a “metabolic budget system” to balance the energy requirements of the cell against the requirements of a growing and dividing cell.

There are multiple allosteric feedback mechanisms at work controlling the balance between the forward enzyme reaction (to produce ATP and pyruvate) and M₂PK inhibition [resulting in accumulation of intermediate metabolites required for DNA and protein synthesis (7)]. There is a growing literature showing that M₂PK activity can be modulated by acetylation (8), phosphorylation (6, 9), cysteine oxidation (10), and proline hydroxylation (11), providing additional mechanisms for enzyme regulation as well as conferring recognition sites for a diverse range of protein partners (6), including for example HIF (11), HPV E7 (12, 13), and the peptide hormone somatostatin (14).

Switching on the production of the constitutively fully active M₁PK was shown to reverse the Warburg effect and to inhibit tumor growth in mouse xenograft models (3). This result suggests that allosteric activation of M₂PK by pharmacological agents could be of interest, and a number of potent activators have been identified with AC₅₀ (concentration that gives 50% activation) values of approximately 30 nM (15, 16). Currently, the only examples of so-called “natural activators” are three families of weak M₂PK inhibitors with IC₅₀ Values of 10–20 μM that show some selectivity over M₁PK (17).

The results presented here show how M₂PK can be stabilized in three biologically relevant states: an inactive monomer, a distinct inactive T-state tetramer, and an active R-state tetramer (Fig. 1). X-ray structures of the different states show how the tetramer switches between the inactive T-state trapped as a phenylalanine complex and the fully active R-state, which is very similar in structure and enzyme activity to the constitutively fully active M₁PK isoform. From a screen of more than 50 natural metabolites, thyroid hormone triiodo-L-thyronine (T₃) and phenylalanine were identified as the strongest enzyme inhibitors. In cellular assays we show that both T₃ and phenylalanine increase cell proliferation, whereas the addition of the allosteric activator F₁₆BP decreased cell proliferation. These enzymatic, structural, and cellular results provide plausible molecular mechanisms linking cell proliferation with allosteric regulation of M₂PK enzyme activity.

Results and Discussion

M₂PK Exists in Equilibrium Between Inactive Monomer and Active Tetramer. Analytical gel filtration was used to analyze the oligomeric natures of M₁PK and M₂PK. In the absence or presence of the allosteric effector F₁₆BP, M₁PK eluted as a single species with a retention volume of 1.3 mL (Fig. 2), consistent with M₁PK existing only as a tetramer. Under identical conditions (0.1 mg mL⁻¹) M₂PK eluted as a mixed population of...


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, www.pdb.org (PDB ID codes 3SRF, 4FXF, and 4FXD).

1To whom correspondence should be addressed. E-mail: m.walkinshaw@ed.ac.uk.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1217157110/-/DCSupplemental.
Using PEP as a substrate (without effector) M1PYK has an apparent $V_{max}$ value of 346 μmol per min per mg and an $S_{0.5(PEP)} = 0.05$ mM; addition of the effector F16BP made essentially no difference to the kinetics. By contrast, addition of effector F16BP to M2PYK resulted in a nearly twofold increase in apparent $V_{max}$ (Fig. 2D) and a marked shift in the $S_{0.5(PEP)}$ value from 0.9 to 0.1 mM, with a concomitant drop in cooperativity (from a $n_H$ of 1.2 to 1.0). PEP cellular concentrations are estimated to lie between 0.02 and 0.5 mM (18). Activation of M2PYK by F16BP would therefore increase reaction rates by between four- and 10-fold over this PEP concentration range. For a given protein concentration (~0.03 μM), an increase in F16BP concentration (from ~2 μM to 30 μM) results in marked changes in apparent

![Figure 1](https://www.pnas.org/doi/fig/10.1073/pnas.1217157110)

**Fig. 1.** Allosteric nutrient sensing mechanism also regulates cellular proliferation. X-ray structures of the tetrameric Phe-bound T-state (B) and F16BP-activated R-state (D) are shown as cartoons, with each 50-kDa protomer represented by a rectangular shape showing the effector and active sites. M2PYK exists in equilibrium between tetrameric (C) and enzymatically inactive monomer (A) forms (gray arrows). Phenylalanine (Phe, cyan square) and the thyroid hormone T3 (orange) act as allosteric inhibitors and prevent the tetramer adopting an active R-state conformation. The activator F16BP (green square) clamps the tetramer in an enzymatically active conformation. (E) Addition of F16BP to HCT-116 cells inhibits proliferation, whereas both inhibitors of M2PYK (T3 and Phe) stimulate proliferation.

![Figure 2](https://www.pnas.org/doi/fig/10.1073/pnas.1217157110)

**Fig. 2.** Oligomeric states of M1PYK and M2PYK. (A) Analytical gel-filtration elution profile observed for 10-μL sample injection of 0.1 mg·mL$^{-1}$ M1PYK in the absence (black) and presence (red) of 500 μM F16BP. (B) Same experiment as in A but for M2PYK. (C) Determination of the molar mass of M2PYK using SEC-MALS. Solid black line indicates the trace from the refractive index detector, and red dots are the weight-averaged molecular masses for each 0.5-s slice analyzed. A total of 200 μg of M2PYK was injected onto a Superdex 200 10/300 column. Flow rate was 0.5 mL min$^{-1}$. (D) Concentration response curves observed for the titration of PEP against M2PYK in the presence (blue line) or absence (black line) of saturated F16BP. Error bars are derived from three independent repeat experiments. (E) Analytical gel-filtration elution profile observed for 10-μL sample injection of 0.1 mg·mL$^{-1}$ M2PYK in the absence (black) and presence (red) of 10 μM T3. (F) Analytical gel-filtration elution profiles observed for 10-μL sample injection of 0.5 mg·mL$^{-1}$ M2PYK in the absence (black) and presence (red) of 5 mM Phe. Experiments in which Phe was added to the running buffer could not be monitored at 214 nm because Phe saturated the absorbance. Monitoring M2PYK, that has a low extinction coefficient at 280 nm, required a higher M2PYK concentration, which increased lower limits from 0.1 mg/mL to 0.5 mg/mL. Thermal shift assays performed at 0.5 mg/mL M2PYK (Fig. 5B) provide complementary results to those observed by gel filtration.

Kinetic profiles of M1PYK and M2PYK were determined for phosphoenolpyruvate (PEP) in the presence or absence of the allosteric effector F16BP at 37°C and are summarized in Table 1.
Table 1. Kinetic parameters for PEP

<table>
<thead>
<tr>
<th>Protein</th>
<th>Apparent ( V_{\text{max}} ) (( \mu \text{mol per min per mg} ))</th>
<th>( S_{0.5\text{PEPP}} ) (mM)</th>
<th>( n_H )</th>
</tr>
</thead>
<tbody>
<tr>
<td>M2PYK-WT</td>
<td>116.3 (3.3)</td>
<td>0.86 (0.08)</td>
<td>1.2</td>
</tr>
<tr>
<td>M2PYK-WT + 500 µM F168P</td>
<td>212.9 (1.4)</td>
<td>0.10 (0.10)</td>
<td>1.0</td>
</tr>
<tr>
<td>M1PYK-WT</td>
<td>345.8 (12.8)</td>
<td>0.05 (0.05)</td>
<td>1.0</td>
</tr>
<tr>
<td>M1PYK-WT + F168P</td>
<td>355.6 (11.5)</td>
<td>0.05 (0.05)</td>
<td>1.0</td>
</tr>
<tr>
<td>M2PYK-R489A</td>
<td>87.0 (3.9)</td>
<td>0.27 (0.11)</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Errors shown in parentheses. SEs for \( n_H \) are 0.1-0.2. Kinetic assays were carried out at 37 °C at pH 7.4. Assay conditions: PBS (8.1 mM Na₂HPO₄, 1.5 mM KH₂PO₄, 2.7 mM KCl, and 137 mM NaCl, pH 7.4) buffer with saturating [ADP] = 2 mM, [KCl] = 100 mM, and [MgCl₂] = 10 mM in the presence or absence of 500 µM of F168P. PEP was serially diluted for 5 mM to 0.04 mM. The corresponding kinetic data are shown in Fig. S1.

The stabilization effects of PYK modulators were analyzed using a thermal denaturation assay (Table 2 and Fig. S2). An increase in melting temperature (\( T_m \)) reflects ligand binding and reduced conformational flexibility. The addition of the allosteric activator F168P to M2PYK apoenzyme shows the most dramatic increase in the \( T_m \) from 48 °C to 55 °C. The addition of inhibitory amino acids phenylalanine, alanine, and tryptophan resulted in significant increases in \( T_m \) values (2–4 °C). The addition of norphenylephrine and T3 to M2PYK resulted in \( T_m \) shifts of 3 °C. At identical concentrations, these ligands had no effect on the \( T_m \) of M1PYK, confirming the enzymatic results and the preference of these ligands for binding to M2PYK over M1PYK.

X-Ray Structural Studies of R-State M1PYK, R-Stage M2PYK, and T-State M2PYK. Peg-in-hole geometry locks M1PYK and active M2PYK in identical conformations. Both the human unligated M1PYK and M2PYK complexed with ATP, oxalic acid, and F168P (M2PYK-ATP/OX/F168P; active R-state) were crystallized at a physiologically relevant pH of 7.2 and the structures refined at 2.85 and 2.55 Å (Table S2), respectively. The R-state complex of M2PYK ATP/OX/F168P provides an example of a structure of a mammalian allosteric PYK with ATP bound in the active site. The human M1PYK structure presented here differs by 16 amino acid residues from the previously published rabbit (2, 23) M1PYK structure.

The M2PYK-ATP/OX/F168P complex adopts a structure (Fig. 3) similar to that of constitutively fully active M1PYK, with an rms fit for all Cα atoms (excluding the effector loops and the flexible B-domains) of ~0.5 Å. The only region exhibiting any significant difference corresponds to the 22 amino acid splice difference (Fig. 3 B and C) between M1PYK and M2PYK, which makes up the “β-β” dimer interface between the C-domains in the tetramer. Key differences in hydrogen bonding across the C-C interface involve Lys421 (Table S2). In the M1PYK structure, C41 and C42 helices form a tight clasp around Lys421, which makes a salt bridge with Glu409 and three additional hydrogen bonds with Ser401, Ser404, and Tyr443. In the M2PYK structure, the backbone of the linker between the C41 and C42 helices (41-Pro-Ile-Thr-Ser-Asp-Pro-Pro) adopts a significantly different conformation compared with the M1PYK linker (41-Ser-His-Ser-Thr-Asp-Leu), which pushes the helices further apart by 2.5 Å. This has the effect of relaxing the very tight peg-in-hole binding that was observed in the M1PYK structure, in which Lys421 acts as the peg and residues 390–420 form the hole (Fig. 3B).

Errors shown in parentheses. *Thermal shift assays were performed at pH 7.4 in PBS buffer using 0.5 mg/mL of enzyme in the absence and presence of 1 mM ligand. The corresponding thermal melt data are shown in Fig. S2.

Morgan et al.

PNAS | April 9, 2013 | vol. 110 | no. 15 | 5883

Table 2. Inhibition and thermal shift assays

<table>
<thead>
<tr>
<th>Ligand</th>
<th>( AC/C_{50} ) (µM)</th>
<th>( \Delta Tm ) (°C)*</th>
<th>( AC/C_{50} ) (µM)</th>
<th>( \Delta Tm ) (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F168P</td>
<td>6.5 (0.3)</td>
<td>7</td>
<td>No effect</td>
<td>No shift</td>
</tr>
<tr>
<td>Ser</td>
<td>&gt;1 mM</td>
<td>0</td>
<td>No effect</td>
<td>No shift</td>
</tr>
<tr>
<td>His</td>
<td>&gt;1 mM</td>
<td>0</td>
<td>No effect</td>
<td>No shift</td>
</tr>
<tr>
<td>Phe</td>
<td>240 (0.1)</td>
<td>4</td>
<td>&gt;1 mM</td>
<td>No shift</td>
</tr>
<tr>
<td>Nor</td>
<td>9,300 (1.9)</td>
<td>3</td>
<td>No effect</td>
<td>No shift</td>
</tr>
<tr>
<td>T3</td>
<td>0.072</td>
<td>3</td>
<td>&gt;4 µM</td>
<td>No shift</td>
</tr>
<tr>
<td>Trp</td>
<td>&lt;1 mM</td>
<td>2</td>
<td>No effect</td>
<td>No shift</td>
</tr>
<tr>
<td>Ala</td>
<td>&gt;1 mM</td>
<td>3</td>
<td>No effect</td>
<td>No shift</td>
</tr>
</tbody>
</table>

*Errors shown in parentheses.
Rotation of the protomers pulls Lys421 out of its binding pocket and destroys the peg-in-hole binding that stabilizes the C-C interface in the R-state M2PYK structure (Movie S1).

The rigid body rotation of the protomers is similar to that observed for the T to R transition in *Leishmania mexicana* PYK (LmPYK) (24). In LmPYK the allosteric “rock-and-lock” regulation mechanism is controlled by a concerted rigid-body rocking motion of all four chains between an active (R) and inactive (T) state, with the effector (in this case F26BP) locking the active conformation by the formation of eight salt bridges across the C-C interface of the tetramer. The locking mechanisms that stabilize the R and T states are, however, very different between the two species. In M2PYK the rigid body rotation of the protomers allows the side chains of Trp515 and Arg516 of the (unoccupied) F16BP effector binding loop to swivel out and form salt bridges and hydrogen bonds across the C-C interface, stabilizing the R-state (Fig. 3). The concerted rocking motion of each of the protomers explains the docking across the C-C interface, which can be stabilized in the R-state by the peg-in-hole interaction or in the T-state by the Trp/Arg interactions as described in the phenylalanine complex. As the protomers rock 13° from T- to R-state in response to effector binding, the Trp-stabilized T-state interactions are broken and the disordered Lys421 (the peg) slots into the hole (formed by residues 390–420), thereby stabilizing the R-state (Fig. 3 A and B and Movies S1 and S2).

The concerted rocking motion of each of the protomers explains at the molecular level how the effector molecule F16BP can bind over 40 Å away from the active site and enhance enzymatic activity. This motion is therefore similar in a number of ways to the rock-and-lock mechanism of LmPYK, although the residues involved in locking the protomers in a given T or R state are not conserved between the species. The 13° rigid body “rock” of M2PYK places Arg342 in position to prime the active site by stabilizing the short glycine-rich A6’ helix (Gly-Asp-Leu-Gly-Ile-Glu-Pro) of an adjacent protomer (Fig. S3). The involvement of adjacent protomers in shaping the active site provides a clear explanation for the inactivity of monomeric PYK and also therefore an explanation of the inhibitory effect of T3, which stabilizes monomeric M2PYK.

**Inhibition of M2PYK by Phenylalanine and T3 Enhance Cell Proliferation.** M2PYK is frequently up-regulated in cancer cells (27), and it has been suggested that inactivating M2PYK would block metabolic flux, allowing build-up of glycolytic intermediates for macromolecular biosynthesis and tumor growth (28, 29). The structural and biochemical results described above provide mechanisms for phenylalanine, T3, and F16BP to act as allosteric inhibitors and activators with a high specificity for M2PYK over M1PYK. It was of interest therefore to determine whether these compounds would have an effect on cell growth.

We selected the cell line HCT-116 for this study because it is known to overexpress M2PYK (30). Addition of 5 mM Phe or 20 μM T3 to the cell culture media significantly increased cell proliferation compared with vehicle treated cells, whereas
addition of 1 mM F16BP resulted in complete inhibition of cell growth (Fig. 1E). It has previously been shown that although F16BP is highly negatively charged it can enter the cell (31).

In vitro the enzymatic inhibition of P58 by T3 can be overcome by addition of high concentrations of F16BP (20). Another study showed a similar effect, with inhibition by phenylalanine (25). We were able to show comparable effects in cellular proliferation experiments, whereby the addition of 1 mM F16BP was able to abrogate the effects of both T3 and phenylalanine (Fig. 1E), providing strong evidence that M2PYK is indeed the cellular target. Together these data suggest that allosteric M2PYK activation can play a dominant role in regulating cancer cell growth.

There is increasing interest in M2PYK as a potential anti-proliferative drug target, and stimulation of M2PYK activity (32–34) or inhibition (17) have both been explored. The reduction in size of tumor allografts observed using synthetic activators of M2PYK (34) fit with our observations that activation of M2PYK leads to the inhibition of proliferation of HCT-116 cells and supports the approach of developing small-molecule M2PYK activators for cancer therapy.

**M2PYK as a Nutrient Sensor and Regulator of Cell Proliferation.** In this article we have described the detailed regulatory mechanisms of three small-molecule inhibitors and activators. The structural and biophysical data describe two molecular mechanisms for inhibiting M2PYK, as summarized in Fig. 1. T3 traps M2PYK in an inactive monomeric state, whereas phenylalanine traps M2PYK in an inactive tetrameric T-state. Despite these different inhibitory mechanisms each inhibitor has similar dramatic effects on cellular proliferation, suggesting that their interactions with M2PYK are biologically relevant.

There is a large body of published work on the biological roles of T3 (35). The most studied properties of thyroid hormones relate to their activities as gene regulators. However, there is a pool of unbound T3/T4 available at approximately nanomolar concentration (36), which regulates a number of nongenomic actions. In two breast cancer cell lines, increased T3 levels correlate with the degree of Warburg phenotype and increased level of M2PYK (36).

F16BP is effective in reducing the tissue damage associated with ischemia due to hypo-perfusion, and at concentrations in the millimolar range F16BP suppresses T-cell proliferation (37), which provides a potential therapy against inflammation and sepsis. Tyrosine phosphorylation has been shown to prevent binding of F16BP, thus preventing enzyme activation, and the ability of M2PYK to bind F16BP was inversely correlated with tumor growth in xenograft mice (38). In this context F16BP binding to M2PYK is acting as an inhibitor of cell proliferation, which correlates with our result.

Several reviews have mentioned that amino acids affect human M2PYK activity but without detailed kinetic data (6, 29), and one study on rabbit kidney PYK showed the poor inhibition by phenylalanine of rabbit M1PYK relative to allosterically activated PYK (25). The effect of phenylalanine on cancer cell proliferation has not been previously published, although in some early work a phenylalanine restricted dietary regimen has been shown to result in significant inhibition of tumor growth in mice (39, 40). It is compelling that phenylalanine and T3, which inhibit M2PYK enzyme activity, both show the same cellular phenotype in HCT-116 cells. Interestingly, earlier work showed that the effect of T3 on epithelial cell replication can be replaced by phenyalanine, and transformation strongly reduces both T3 and phenylalanine requirements for growth (41).

Phenylalanine is one of the essential amino acids and cannot be synthesized by mammals and requires constant monitoring. The allosteric pocket identified in the M2PYK-Phe crystal structure may therefore provide a potential feedback mechanism to block enzyme activity when phenylalanine is abundant in the cell, allowing metabolite build-up and cell proliferation. The various oligomeric states of M2PYK described here (Fig. 1) suggest how M2PYK may be acting as a biological nutrient sensor for the cell, responding directly or indirectly to fluctuations in oxygen (11), essential amino acids, hormones, and glucose.

**Materials and Methods**

**M1PYK and M2PYK Production and Activity Measurements.** M1PYK and M2PYK were expressed and purified as described in SI Materials and Methods. Site-directed mutagenesis of M2PYK cDNA was performed using the QuikChange mutagenesis kit from Stratagene, according to the manufacturer’s instructions. Enzyme activity measurements in the absence and presence of modulators were performed using the standard lactate dehydrogenase coupled assay (SI Materials and Methods).

**Cryrstallization and Structure Determination.** Single crystals of M1PYK and M2PYK were obtained as described in SI Materials and Methods, and diffractive data were collected at the Diamond synchrotron radiation facility in Oxfordshire, United Kingdom on beamline I03 to a resolution of 2.35 Å (M2PYK-ATP/OX/F16BP), 2.9 Å (M2PYK-R489A-Phe), and 2.85 Å (M1PYK). All datasets were obtained from a single crystal flash-frozen in liquid nitrogen at 100 K. Structures were solved by molecular replacement as described in SI Materials and Methods. Atomic coordinates and the experimental structure factors for all structures have been deposited in the Protein Data Bank, with the following codes, M1PYK (3RF), M2PYK-ATP/OX/F16BP (4FXF), and M2PYK-R489A-Phe (4FXJ).
Analytical Gel Chromatography. M1PYK and M2PYK were purified under identical conditions, and highly purified samples of both isoforms were loaded independently onto a Superdex 200 PC 3.2/30 gel filtration column. Unless stated otherwise, protein samples were analyzed at physiologically relevant concentrations (0.1 mg/mL) (18). Ten-microliter samples were injected, and the column flow rate was maintained at 0.1 μL min⁻¹. Separations and equilibration steps were performed in PBS without calcium and magnesium (PBS-CM) or PBS-CM supplemented with the appropriate concentration of F16BP, T3, or phenylalanine at 26 ºC. Protein peaks were monitored using absorbance at both 280 and 214 nm. All samples were incubated overnight at 26 ºC before analysis.

SEC-MALS Analysis. SEC was carried out at room temperature at a flow rate of 0.5 mL min⁻¹ using a Superdex 200 10/300 GL. The Superdex column was connected in-line with the following detectors: UV detector, a light scattering detector (Wyatt Technology), and a refractometer.

Thermal Shift Assay. Thermal shift assays were performed essentially as described previously (24), except PBS buffer was used throughout.

Cell Growth Experiments. HCT-116 growing (37 ºC and 5% CO₂) exponentially in McCoy’s 5A media plus 10% FCS (MS) were suspended with trypsin EDTA (trypsin, 0.05%; EDTA, 0.02%), and ~32,000 cells per well (1.6 mL of 20,000 cells per mL) were plated into sterile six-well (35-mm) plastic culture dishes. After sufficient time for the cells to become adherent had elapsed (12–16 h) an Alamar blue assay (Invitrogen) was performed to ensure equivalent cell density between wells as per the manufacturer’s instructions. The medium was changed (1.6 mL of media per well) to McCoy’s 5A media plus 10% dialyzed FCS (Dundee Cell Products, catalog no. D51002) supplemented with either T3 (a 25-mM stock solution was prepared in 100 mM NaOH), F16BP (a 100-mM stock solution was prepared in McCoy’s 5A media, and the pH adjusted to 7.4 with NaOH or phenylalanine (an 80-mM stock solution was prepared in McCoy’s 5A media). All ligand stocks were filtered through a 0.2-μm filter. Cells were then grown for a further 72 h and were collected by suspension in trypsin-EDTA and counted in a hemocytometer. Ligands used in this study interfere with metabolic pathways (TCA and glycolysis), leading to difficulties interpreting metabolic-based proliferation assays.

ACKNOWLEDGMENTS. We thank Dr. J. Dornan for excellent advice and practical help, and the staff at the Synchrotron facilities at Diamond, United Kingdom. This project has been funded by the Medical Research Council, The Centre for Translational and Chemical Biology and the Edinburgh Protein Fractionation Facility were funded by the Wellcome Trust and the Biotechnologi and Biological Sciences Research Council. J.R.O. was funded by a Wellcome Clinical Training Fellowship 094417/Z/10/Z.


PNAS